@article{4721e5f14e5d415480aa6971f86c172d,
title = "Deferasirox for Transfusion-Dependent Patients with Myelodysplastic Syndromes: Safety, Efficacy, and Beyond (GIMEMA MDS0306 Trial)",
abstract = "In the absence of randomized, controlled trial data to support iron chelation therapy in transfusion-dependent patients with myelodysplastic syndromes (MDS), continued evidence from large prospective clinical trials evaluating the efficacy and safety of iron chelation therapy in this patient population is warranted.",
keywords = "Chelation Therapy, Deferasirox (DFX), Iron Chelation, Iron Overload, Myelodysplastic Syndromes, Safety, Serum Ferritin, Chelation Therapy, Deferasirox (DFX), Iron Chelation, Iron Overload, Myelodysplastic Syndromes, Safety, Serum Ferritin",
author = "Voso, {Maria Teresa} and Emanuele Angelucci and Valeria Santini and {Di Tucci}, {Anna Angela} and Giulia Quaresmini and Carlo Finelli and Antonio Volpe and Giovanni Quarta and Flavia Rivellini and Grazia Sanpaolo and Daniela Cilloni and Flavia Salvi and Giovanni Caocci and Alfredo Molteni and Daniele Vallisa and Susanna Fenu and Lorenza Borin and Giancarlo Latte and Giuliana Alimena and Alfonso Piciocchi and Paola Fazi and Marco Vignetti and Sante Tura",
year = "2014",
doi = "10.1111/ejh.12300",
language = "English",
pages = "N/A--N/A",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Oxford : Blackwell",
}